Taevas
SouthMarket Entry & Growth in South
South Africa is the continent's most sophisticated life-sciences market, anchored by SAHPRA's rigorous regulatory framework and a growing private healthcare sector. Taevas delivers end-to-end market entry support so your product reaches South African pati
SAHPRA Registered
GMP Compliant
ISO 13485
$5.8B+
Healthcare Market Size
Top 3
Largest Pharma Market in Africa
60M+
Population
9
Provinces Covered
Industries We Support
Four Industries. One South Team.
Select an industry to see regulatory pathways, services, and how Taevas supports your South market entry.
Medical Devices & Equipment
South African Health Products Regulatory Authority (SAHPRA)
South Africa's medical device market is valued at over $700 million and is regulated by SAHPRA under a risk-based classification system spanning Class A (lowest risk) to Class D (highest risk). SAHPRA's Medical Devices and In Vitro Diagnostics unit requires full technical files, quality management system certification, and local responsible person designation. Taevas manages your end-to-end SAHPRA submission, local representation, and post-market obligations so you can focus on commercial growth.
Regulatory Pathways
Mandatory
SAHPRA Device Registration
All medical devices sold in South Africa must be registered with SAHPRA. Class A devices follow a notification pathway while Class B, C, and D require full technical dossier review with clinical evidence.
Required
Quality Management Certification
Manufacturers must hold ISO 13485 certification and evidence of compliance with SAHPRA's Good Manufacturing Practice requirements before a device application is accepted.
Mandatory
Import Permit & Customs Clearance
A valid SAHPRA import permit is required for all regulated health products entering South Africa. Taevas coordinates permit applications and Customs and Excise clearance through SARS.
Ongoing
Post-Market Surveillance
Registered device holders must maintain a post-market surveillance system, report serious incidents to SAHPRA within prescribed timelines, and conduct periodic safety update reviews.
Our Services for Medical Devices in India
Why Taevas South
Why Global Brands Choose Taevas for South
Taevas combines deep SAHPRA regulatory expertise with an established commercial network across South Africa's nine provinces, giving international life-sciences brands a single, accountable partner from first submission to sustainable revenue.
Regulatory
SAHPRA Regulatory Mastery
Our South Africa team has navigated SAHPRA submissions across medical devices, pharmaceuticals, complementary medicines, and cosmetics, giving your dossier the best chance of first-time approval.
Market Access
Pan-African Market Reach
South Africa serves as the gateway to sub-Saharan Africa. Taevas leverages its Johannesburg hub to extend your brand into neighbouring SADC markets alongside your South African launch.
Speed
Accelerated Time to Market
Our pre-built relationships with SAHPRA reviewers, customs brokers, and national distributors compress your typical South Africa entry timeline from years to months.
Distribution
Established Distributor Network
Taevas maintains active partnerships with leading South African distributors covering private hospital groups, independent pharmacies, retail chains, and public sector tender channels.
KOL Network
KOL and Clinical Engagement
We connect your brand with influential South African clinicians, academic medical centres, and professional associations to build the evidence base and advocacy needed for market adoption.
Track Record
Proven Track Record
Taevas has supported multiple international life-sciences brands through successful South Africa market entries, with a consistent record of on-time SAHPRA submissions and compliant commercial launches.
Get Started
Ready to Enter the South Market?
Book a free consultation with our South Africa specialists and receive a tailored market entry roadmap covering SAHPRA registration, distributor strategy, and your path to first revenue.
Free South assessment
SAHPRA-certified specialists
National distribution coverage across all 9 provinces
End-to-end to revenue